HBM BioMed China

Harbour BioMed (HBM Holdings) is a global, clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in oncology and immunology. The company leverages its proprietary Harbour Mice® platforms to generate fully human monoclonal antibodies in both traditional (H2L2) and heavy chain-only (HCAb) formats, alongside its HBICE® platform for bispecific immune cell engagers. Its lead clinical programs include batoclimab (HBM9161), an anti-FcRn antibody for autoimmune diseases, and porustobart (HBM4003), a next-generation anti-CTLA-4 antibody. Harbour BioMed has established a robust network of global collaborations with partners such as AstraZeneca, Pfizer, and Otsuka, and operates through its sub-brands Harbour Therapeutics and Nona Biosciences. The company is headquartered in Shanghai with major operations in Suzhou, Cambridge (US), and Rotterdam (NL).